Why the study?
The emergence of resistant viruses is a major obstacle to successful therapy of viral infections, prompting investigation into viral resistance during treatment with sCAR-Fc against CVB infections.
Repetitive use of sCAR-Fc against Coxsackievirus B3 leads to the emergence of resistant mutants, though these mutants exhibit lower viral fitness.
Answers are grounded in this paper and cite their sources.
May support sCAR-Fc durability against CVB3; leaves open clinical translation and resistance monitoring.
The emergence of resistant viruses is one of the most frequent obstacles preventing successful therapy of viral infections, representing a significant threat to human health. We investigated the emergence of resistant viruses during treatment with sCAR-Fc, a well-studied, highly effective antiviral molecule against CVB infections. Our data show the molecular aspects of resistant CVB3 mutants that arise during repetitive sCAR-Fc usage. However, drug resistance comes at the price of lower viral fitness. These results extend our knowledge of the development of resistance by coxsackieviruses and indicate potential limitations of antiviral therapy using soluble receptor molecules.
No takes yet. Share an insight, caveat, or question.
Pinkert et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: